# A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

> **NCT03298906** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Esketamine
- **DRUG:** Ticlopidine

## Key facts

- **NCT ID:** NCT03298906
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-26
- **Primary completion:** 2017-11-27
- **Final completion:** 2017-11-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03298906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03298906, "A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03298906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*